The Menopausal Hot Flashes Market is expected to register a CAGR of 3.3% during the forecast period. Hot flashes is a sudden feeling of warmth, which is usually most intense over the chest, neck, and face. Hot flashes cause redness of the skin (called as flushing) and excessive sweating. Hot flashes generally occur due to menopause when menstrual periods become irregular and eventually stop. In fact, hot flashes are the most common symptom of the menopausal transition (which includes stages such as pre-menopause, perimenopause, and post-menopause). Hot flashes occurrence varies among women and can range from a few a week to several hours. Some of the symptoms during a hot flash are rapid heartbeat, flushed appearance with red, blotchy skin, perspiration, mostly on your upper body, a sudden feeling of warmth spreading through your upper body and face and so on. Hot flashes can vary in intensity and frequency. On average, symptoms of hot flashes persist for more than seven years or Sometimes in some women, it may be for more than 10 years. Hot flashes cause due to changes in reproductive hormones which becomes more sensitive to slight changes in body temperature. Factors such as smoking, obesity, ethnicity may increase risk in the development of hot flashes.

According to the study published in The Lancet Journal, an estimated 1 billion women globally, will be older than 50 years, within the next 25 years and therefore likely to be reporting menopause or postmenopausal conditions. In addition, approximately 73% of postmenopausal women, experience hot flashes (vasomotor symptoms) and may result in fatigue, decreased cognitive function and sleep disturbances which lead to a reduction in their quality of life and an increased use of medical resources.

Increasing incidence of menopausal hot flashes, increasing number of new drug approvals for the treatment and rising awareness regarding menopause health are the key driving factors in menopausal hot flashes market.

Key Market Trends

Estrogen-Only Medicines Segment is Expected to Hold a Major Market Share in the Menopausal Hot Flashes Market

Estrogen-only medicines help in boosting women’s hormone levels and minimize symptoms of the menopausal transition, including hot flashes. Some of the FDA approved estradiol-containing products to treat hot flashes are Alora, Estraderm, Estrogel, Evamist, Vivelle, Climera, Divigel and Estrace.

As per The International Menopause Society, women aged below 45 years who are postmenopausal have a 30% lower risk of breast cancer when compared to women who become premenopausal between 45-54 years are at greater risk of breast cancer. Estrogen-only medicines segment hold a significant market share in the menopausal hot flashes market and is anticipated to show a similar trend over the forecast period because no other available drug is as effective as estrogen, for example, Premarin was the largest selling estrogen product in the year 2014 which recorded over billion sales in that year.

Increasing incidence of menopausal hot flashes and technological advancements in the development of new drugs are the key driving factors in the Estrogen-only medicines segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global menopausal hot flashes market due to the increasing incidence of menopausal hot flashes, rising awareness regarding menopause health, and the presence of a larger percentage of older women in the overall population in this region. According to the North American Menopause Society, about 75% of North American women experience hot flashes during perimenopause, and approximately a quarter of them experience enough discomfort to seek relief from their clinicians. Furthermore, technological advancements in the development of new drugs, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Menopausal Hot Flashes Market is fragmented competitive and consists of several major players. A large portion of the market share is taken up by small and mid-sized companies that produce generic treatment options. Some of the companies which are currently dominating the market are Allergan Plc, Bayer AG, Novartis AG, Pfizer, Inc, Novo Nordisk Corporation, Hisamitsu Pharmaceutical Co., Inc, Merck & Co., Inc, and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support